GLP-1 Agonists Weight Loss Dual GIP/GLP-1 Agonists Multiple Incretin Agonists Gastrointestinal Peptides Under research

Retatrutida

Also known as: LY3437943, Agonista GGG

Retatrutide is an investigational next-generation triple incretin agonist. It differs from peptides like Semaglutide (GLP-1 agonist) or Tirzepatide (GLP-1/GIP) by binding to and activating three different hormone receptors: GLP-1, GIP, and Glucagon. This "triple G" approach gives it unprecedented power in stimulating lipid metabolism and profound weight loss, surpassing the efficacy of single and dual agonists.

Mechanism of action

GLP-1: Suppresses appetite in the brain and delays gastric emptying.
GIP: Improves insulin sensitivity and enhances the GLP-1 effect.
Glucagon (GCG): Drastically increases energy expenditure (calorie burning) and stimulates rapid fat mobilization in the liver and adipose tissue.

Uses & indications

Severe Obesity: Potential to replace bariatric procedures.
Type 2 Diabetes: Blood glucose level control.
Fatty Liver (NAFLD/NASH): Superior action in clearing fat from organ tissues due to the glucagon receptor.

Effects

Massive body weight loss (up to 24% in 48 weeks in Phase 2 trials), drastic reduction of hepatic steatosis, and general lipid profile improvement.

Considerations & contraindications

Side effects include transient nausea, vomiting, and diarrhea upon initiation, plus possible temporary increases in heart rate.
Requires slow dose titration for tolerance.

Regulatory approval

In Phase 3 clinical trials. Not yet approved for public sale.

Dosage

In studies, starting at 1mg weekly or 2mg monthly, and gradually titrated up to a maximum of 12mg per week based on tolerance.

Storage

Keep refrigerated at 2°C to 8°C.

Technical data

Regulatory status Under research

Molecular weight 4731.33 Da

Half-life Aproximadamente 6 días

Administration routes Subcutánea semanal